Retatrutide vs Tirzepatide: Trial Comparison

Summary

Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual mechanism of tirzepatide. Phase 2 retatrutide data reported larger mean weight reduction at 48 weeks than tirzepatide's phase 3 results, but the two have never been compared head to head, and phase 2 populations are not comparable to phase 3 populations.

Last reviewed 2026-09-01

What it is

A comparison of two multi-receptor incretin agonists: tirzepatide, a GIP/GLP-1 dual agonist with completed phase 3 programmes, and retatrutide, an investigational GIP/GLP-1/glucagon triple agonist.

Tirzepatide's SURPASS and SURMOUNT programmes reported from 2021. Retatrutide phase 2 obesity results were published in 2023; phase 3 TRIUMPH trials are ongoing.

Both are synthetic multi-agonist peptides developed from incretin pharmacology.

The comparison tests whether adding a third receptor — glucagon, which raises energy expenditure — produces additive benefit or additive burden.

How it works

In plain terms

Both mimic gut hormones that reduce appetite and slow stomach emptying. Retatrutide adds a third signal that increases how much energy the body burns, rather than only reducing how much is eaten.

Technical detail

Tirzepatide is a GIP receptor and GLP-1 receptor dual agonist, biased toward GIP receptor affinity. Retatrutide adds glucagon receptor agonism. Glucagon receptor activation increases hepatic energy expenditure and lipolysis, which in principle contributes weight reduction through a route independent of appetite suppression — but it also raises hepatic glucose output, requiring the incretin components to offset it. The balance between the three activities is the central design problem.

Pathways involved

GLP-1R: satiety, delayed gastric emptying, glucose-dependent insulin release
GIPR: insulin secretion and adipose tissue effects
GCGR (retatrutide only): hepatic lipolysis and energy expenditure

Current research

Laboratory research

Receptor selectivity and potency profiles are published for both molecules.

Animal research

Rodent models showed additive weight reduction from glucagon receptor addition, with energy expenditure increases not seen with dual agonism alone.

Human research

Tirzepatide's SURMOUNT-1 reported roughly 20.9% mean weight reduction at 72 weeks on the highest dose. Retatrutide's phase 2 obesity trial reported approximately 24.2% at 48 weeks on the highest dose. These figures come from different trial phases, populations, durations and titration schedules, so the difference cannot be treated as a measured head-to-head result. Gastrointestinal adverse events were dose-related in both; retatrutide phase 2 also reported dose-dependent heart rate increases.

Ongoing research

Phase 3 TRIUMPH trials for retatrutide are the first data that will support firmer conclusions.

What is being investigated

Whether glucagon receptor addition improves weight outcomes beyond dual agonism
Energy expenditure contribution versus appetite suppression
Heart rate and hepatic glucose effects of triple agonism
Tolerability at matched titration schedules

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Cross-trial comparison of phase 2 and phase 3 results is not valid evidence of superiority
Retatrutide has no completed phase 3 safety data and is not approved anywhere
Glucagon receptor agonism raises hepatic glucose output and has shown dose-dependent heart rate increases
Gastrointestinal adverse events are common with both mechanisms
Long-term outcome data beyond weight endpoints is limited for both

Evidence ratings

Tirzepatide human data

Strong

Completed phase 3 programmes with large populations.

Retatrutide human data

Preliminary

Phase 2 only; phase 3 ongoing.

Head-to-head comparison

None

No direct comparative trial has been conducted.

Comparisons

Tirzepatide vs semaglutide

The one comparison with direct trial data.

Cagrilintide vs semaglutide

A different mechanism class.

References

[1]Retatrutide phase 2 obesity trial — PubMed / NEJM, 2023
[2]SURMOUNT-1 tirzepatide obesity trial — PubMed / NEJM, 2022
[3]TRIUMPH retatrutide programme — ClinicalTrials.gov, ongoing
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

Is retatrutide stronger than tirzepatide?+

Phase 2 retatrutide figures are numerically larger, but no head-to-head trial exists and phase 2 results are not comparable to phase 3 results.

What is the mechanistic difference?+

Tirzepatide targets GIP and GLP-1 receptors; retatrutide adds glucagon receptor agonism, which raises energy expenditure.

Is retatrutide approved?+

No. It remains investigational, with phase 3 TRIUMPH trials ongoing.

Why does glucagon agonism help weight loss?+

Glucagon receptor activation increases hepatic lipolysis and energy expenditure, adding a route independent of appetite reduction.

Do both cause gastrointestinal side effects?+

Yes. Nausea, vomiting, diarrhoea and constipation are dose-related and common across incretin agonists.

What weight reduction did SURMOUNT-1 report?+

Approximately 20.9% mean reduction at 72 weeks on the highest tirzepatide dose.

What did the retatrutide phase 2 trial report?+

Approximately 24.2% mean reduction at 48 weeks on the highest dose, in a phase 2 obesity population.

When will a fair comparison be possible?+

Only after retatrutide phase 3 results are published, and strictly speaking only with a direct head-to-head trial.

Continue your research

Retatrutide research

Tirzepatide research

Incretin mechanisms